Journal article icon

Journal article

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials

Abstract:
Background and Aims Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods Patient-level data from Phase 3 randomised controlled trials [RCTs] of vedolizumab ... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjy047

Authors


Feagan, BG More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM Experimental Medicine
Oxford college:
Linacre College
Takeda Pharmaceutical Company Ltd More from this funder
Publisher:
Oxford University Press Publisher's website
Journal:
Journal of Crohn's and Colitis Journal website
Volume:
12
Issue:
8
Pages:
905–919
Publication date:
2018-05-17
Acceptance date:
2018-05-01
DOI:
EISSN:
1876-4479
ISSN:
1873-9946
Pubs id:
pubs:854561
URN:
uri:909008e1-9735-4259-8597-f37f4782f20e
UUID:
uuid:909008e1-9735-4259-8597-f37f4782f20e
Local pid:
pubs:854561

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP